TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
Delayed Japan Exchange  -  02:00 2022-07-01 am EDT
3759.00 JPY    0.00%
07/01Takeda's Takhzyro Shows 94.8% Reduction in Hereditary Angioedema Attacks in Phase 3 Trial in Children
MT
06/30TAKEDA PHARMACEUTICAL : Phase 3 SPRING study data presented at EAACI
PU
06/30Takeda's TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: March 2019 2020 2021 2022 2023 2024
Capitalization1 7 029 1615 153 3646 229 9715 423 454--
Enterprise Value (EV)1 12 054 7439 609 0549 862 5228 919 1708 668 1378 143 511
P/E ratio 40,0x118x16,6x23,8x18,9x19,6x
Yield 3,98%5,44%4,52%5,15%4,79%4,79%
Capitalization / Revenue 3,35x1,57x1,95x1,52x1,56x1,63x
EV / Revenue 5,75x2,92x3,08x2,50x2,34x2,28x
EV / EBITDA 25,3x14,0x9,23x8,54x7,21x7,21x
Price to Book 1,36x1,09x1,20x0,95x1,03x1,04x
Nbr of stocks (in thousands) 1 554 7801 557 8491 563 3551 550 444--
Reference price (JPY) 4 5213 3083 9853 4983 7593 759
Announcement Date 05/14/201905/13/202005/11/202105/11/2022--
1 JPY in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: March 2019 2020 2021 2022 2023 2024
Net sales1 2 097 2003 291 2003 197 8123 569 0063 710 6563 566 518
EBITDA1 477 415684 0571 068 9401 043 9951 202 9101 128 922
Operating profit (EBIT)1 205 000100 400509 269460 844545 689511 613
Operating Margin 9,77%3,05%15,9%12,9%14,7%14,3%
Pre-Tax Profit (EBT)1 94 896-60 754366 235302 571430 916407 010
Net income1 109 10044 200376 005230 059310 094297 418
Net margin 5,20%1,34%11,8%6,45%8,36%8,34%
EPS2 11328,0241147199191
Dividend per Share2 180180180180180180
Announcement Date 05/14/201905/13/202005/11/202105/11/2022--
1 JPY in Million
2 JPY
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: March 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2
Net sales1 844 7971 794 400901 294873 289935 275911 300
EBITDA ------
Operating profit (EBIT)1 97 448346 000116 484-1 619172 733145 100
Operating Margin 11,5%19,3%12,9%-0,19%18,5%15,9%
Pre-Tax Profit (EBT)1 61 447284 42572 193-54 047142 225117 050
Net income1 -16 778183 60057 769-11 358104 50889 450
Net margin -1,99%10,2%6,41%-1,30%11,2%9,82%
EPS2 -10,311737,0-6,9567,657,7
Dividend per Share ------
Announcement Date 10/28/202110/28/202102/03/202205/11/2022--
1 JPY in Million
2 JPY
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: March 2019 2020 2021 2022 2023 2024
Net Debt1 5 025 5824 455 6903 632 5513 495 7162 865 9392 341 313
Net Cash position1 ------
Leverage (Debt / EBITDA) 10,5x6,51x3,40x3,35x2,38x2,07x
Free Cash Flow1 -2 507 219961 871617 401999 853784 778812 411
ROE (Net Profit / Equities) 3,00%0,90%7,60%4,20%5,80%5,66%
Shareholders' equity1 3 636 6674 911 1114 947 4345 477 5955 349 1825 259 383
ROA (Net Profit / Asset) 1,06%-0,46%2,85%2,32%3,22%3,06%
Assets1 10 334 963-9 710 01813 209 9379 918 8599 621 6509 710 471
Book Value Per Share2 3 3193 0323 3093 6663 6363 600
Cash Flow per Share2 397403599520620560
Capex1 77 677127 082111 206123 252215 775202 866
Capex / Sales 3,70%3,86%3,48%3,45%5,82%5,69%
Announcement Date 05/14/201905/13/202005/11/202105/11/2022--
1 JPY in Million
2 JPY
Previous periodNext period
Estimates
Key data
Capitalization (JPY) 5 802 197 984 520
Capitalization (USD) 42 911 856 821
Net sales (JPY) 3 197 812 000 000
Net sales (USD) 23 650 356 477
Number of employees 47 347
Sales / Employee (JPY) 67 539 907
Sales / Employee (USD) 499 511
Free-Float 96,8%
Free-Float capitalization (JPY) 5 613 909 896 650
Free-Float capitalization (USD) 41 519 317 048
Avg. Exchange 20 sessions (JPY) 24 577 845 600
Avg. Exchange 20 sessions (USD) 181 772 665
Average Daily Capital Traded 0,4%
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA